Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 10
Submit an article Journal homepage
976
Views
7
CrossRef citations to date
0
Altmetric
Oncology

Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2− metastatic breast cancer

Ravi K. GoyalRTI Health Solutions, Research Triangle Park, Durham, NC, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-1632-036XView further author information
ORCID Icon,
Gebra Cuyun CarterEli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Saurabh P. NagarRTI Health Solutions, Research Triangle Park, Durham, NC, USA; View further author information
,
Emily N. SmythEli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Gregory L. PriceEli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Yu-Jing HuangEli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Li LiEli Lilly and Company, Indianapolis, IN, USA; View further author information
,
Keith L. DavisRTI Health Solutions, Research Triangle Park, Durham, NC, USA; View further author information
&
James A. KayeRTI Health Solutions, Waltham, MA, USAView further author information
 show all
Pages 1699-1710 | Received 18 Dec 2018, Accepted 02 May 2019, Published online: 12 Jun 2019

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ravi K. Goyal, Gebra Cuyun Carter, Saurabh P. Nagar, Emily Nash Smyth, Gregory L. Price, Rohan C. Parikh, Yu-Jing Huang, Li Li, Keith L. Davis & James A. Kaye. (2021) Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2– metastatic breast cancer in the United States. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 699-710.
Read now

Articles from other publishers (6)

Ching-Yuan Chang, Bobby L. Jones, Juan M. Hincapie-Castillo, Haesuk Park, Coy D. Heldermon, Vakaramoko Diaby, Debbie L. Wilson & Wei-Hsuan Lo-Ciganic. (2024) Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors. Breast Cancer Research and Treatment 204:3, pages 561-577.
Crossref
Ravi K. Goyal, Hua Chen, Susan M. Abughosh, Holly M. Holmes, Sean D. Candrilli & Michael L. Johnson. (2023) Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study. Cancer 129:7, pages 1051-1063.
Crossref
Ravi K. Goyal, Holly M. Holmes, Hua Chen, Susan Abughosh, Sean D. Candrilli & Michael L. Johnson. (2023) Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States. Breast Cancer Research and Treatment 198:1, pages 159-166.
Crossref
Kevin BerriosAlexandra BurumEunae JeongLixian Zhong. (2022) Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis. Journal of Managed Care & Specialty Pharmacy 28:11, pages 1282-1291.
Crossref
Jennifer L. Caswell-Jin, Alison Callahan, Natasha Purington, Summer S. Han, Haruka Itakura, Esther M. John, Douglas W. Blayney, George W. SledgeJrJr, Nigam H. Shah & Allison W. Kurian. (2021) Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics:5, pages 600-614.
Crossref
Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, Erika Hamilton, Amelia Zelnak, Louis Fehrenbacher, Erik Jakobsen, Elsa Curtit, Frances Boyle, Eva Harder Brix, Andrew Brenner, Laurence Crouzet, Cristiano Ferrario, Montserrat Muñoz-Mateu, Hendrik-Tobias Arkenau, Nayyer Iqbal, Sramila Aithal, Margaret Block, Soeren Cold, Mathilde Cancel, Olwen Hahn, Teja Poosarla, Erica Stringer-Reasor, Marco Colleoni, David Cameron, Giuseppe Curigliano, Muriel Siadak, Kendra DeBusk, Jorge Ramos, Wentao Feng & Karen Gelmon. (2021) Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). European Journal of Cancer 153, pages 223-233.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.